Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.6 GBX | 0.00% | 0.00% | -8.57% |
03-26 | Scancell doses first patient in melanoma-focused trials | AN |
03-22 | Seneca Growth Capital announces tepid 2023 results | AN |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 78.7M 98.65M 135M |
---|---|---|---|---|---|
Net income 2024 * | -14M -17.55M -23.95M | Net income 2025 * | -14M -17.55M -23.95M | EV / Sales 2024 * | - |
Net Debt 2024 * | 3.88M 4.86M 6.63M | Net Debt 2025 * | 14.94M 18.73M 25.56M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-5.34
x | P/E ratio 2025 * |
-6.35
x | Employees | 51 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.52% |
Current month | -6.34% | ||
1 month | -6.34% | ||
3 months | -8.13% | ||
6 months | -27.55% | ||
Current year | -8.57% |
Managers | Title | Age | Since |
---|---|---|---|
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Director of Finance/CFO | 38 | 23-08-28 | |
Fayaz Master
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 65 | 23-01-31 | |
Ursula Ney
BRD | Director/Board Member | 72 | 19-10-22 |
Linda Durrant
CEO | Chief Executive Officer | 67 | 96-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 9.6 | 0.00% | 148,854 |
24-04-25 | 9.6 | 0.00% | 114,837 |
24-04-24 | 9.6 | 0.00% | 111,474 |
24-04-23 | 9.6 | 0.00% | 319,243 |
24-04-22 | 9.6 | 0.00% | 148,421 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.57% | 98.03M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- SCLP Stock